Baird Upgrades Medpace Hldgs to Outperform, Raises Price Target to $289
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Eric Coldwell has upgraded Medpace Hldgs (NASDAQ:MEDP) from Neutral to Outperform and raised the price target from $270 to $289.
October 24, 2023 | 10:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Medpace Hldgs has been upgraded to Outperform by Baird, with a raised price target of $289.
The upgrade from Neutral to Outperform by Baird indicates a positive outlook for Medpace Hldgs. The raised price target from $270 to $289 suggests that the analyst expects the stock to perform well in the short term. This could potentially lead to an increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100